{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:34Z","timestamp":1789450114581,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.vaccine.2012.07.065","type":"journal-article","created":{"date-parts":[[2012,8,5]],"date-time":"2012-08-05T02:30:12Z","timestamp":1344133812000},"page":"6163-6174","source":"Crossref","is-referenced-by-count":50,"title":["A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial"],"prefix":"10.1016","volume":"30","author":[{"given":"P.C.","family":"Richmond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.07.065_bib0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2012.07.065_bib0010","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.07.065_bib0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"W-135 polysaccharide-protein conjugate vaccines","volume":"92","author":"Pace","year":"2007","journal-title":"Arch Dis Child"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2012.07.065_bib0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.07.065_bib0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"issue":"8346","key":"10.1016\/j.vaccine.2012.07.065_bib0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2012.07.065_bib0035","first-page":"291","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2009","volume":"34","year":"2010","journal-title":"Commun Dis Intell"},{"issue":"2","key":"10.1016\/j.vaccine.2012.07.065_bib0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0050","unstructured":"United Kingdom Health Protection Agency. Meningococcal Reference Unit: Isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998\u20132010*. http:\/\/www.hpa.org.uk\/web\/HPAweb&HPAwebStandard\/HPAweb_C\/1234859712887; [accessed March 2012]."},{"issue":"3","key":"10.1016\/j.vaccine.2012.07.065_bib0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/CDLI.7.3.390-395.2000","article-title":"Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread","volume":"7","author":"Jelfs","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.07.065_bib0060","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","article-title":"Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team","volume":"38","author":"Tondella","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2012.07.065_bib0065","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2012.07.065_bib0075","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1128\/IAI.73.10.6838-6845.2005","article-title":"Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model","volume":"73","author":"Zhu","year":"2005","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2012.07.065_bib0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.07.065_bib0085","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"issue":"7240","key":"10.1016\/j.vaccine.2012.07.065_bib0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nature07769","article-title":"Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates","volume":"458","author":"Schneider","year":"2009","journal-title":"Nature"},{"issue":"37","key":"10.1016\/j.vaccine.2012.07.065_bib0095","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0100","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.07.065_bib0105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2012.07.065_bib0110","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"Pajon","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.07.065_bib0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erv.11.50","article-title":"New frontiers in meningococcal vaccines","volume":"10","author":"Anderson","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2012.07.065_bib0120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2012.07.065_bib0125","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1586\/erv.11.103","article-title":"Neisseria meningitidis B vaccines","volume":"10","author":"Panatto","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0130","series-title":"Notes for Guidance on Preclinical Pharmacologoical and Toxicological Testing of Vaccines","author":"European Medicines Agency","year":"1997"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0135","unstructured":"United States Food and Drug Administration. Guidance for Industry, toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Draft Guidance: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2005."},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2012.07.065_bib0140","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2012.07.065_bib0145","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1016\/j.vaccine.2010.09.038","article-title":"Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage","volume":"28","author":"Ala\u2019aldeen","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0150","first-page":"371","article-title":"Meningococcal vaccine trials","volume":"66","author":"Farrington","year":"2001","journal-title":"Methods Mol Med"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2012.07.065_bib0155","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0160","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0165","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0170","unstructured":"World Health Organization. Requirements for meningococcal polysaccharide vaccine. World Health Organiztion technical report series. Geneva, Switzerland. 1976."},{"issue":"9","key":"10.1016\/j.vaccine.2012.07.065_bib0175","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"7-8","key":"10.1016\/j.vaccine.2012.07.065_bib0180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.07.065_bib0185","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2012.07.065_bib0190","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.07.065_bib0195","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"4","key":"10.1016\/j.vaccine.2012.07.065_bib0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16\u201324 months","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"24","key":"10.1016\/j.vaccine.2012.07.065_bib0205","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2012.07.065_bib0210","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/S0264-410X(99)00036-5","article-title":"Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease","volume":"17","author":"Fischer","year":"1999","journal-title":"Vaccine"},{"issue":"17-18","key":"10.1016\/j.vaccine.2012.07.065_bib0215","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2012.07.065_bib0220","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2012.07.065_bib0225","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.07.065_bib0230","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"9816","key":"10.1016\/j.vaccine.2012.07.065_bib0240","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2012.07.065_bib0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"issue":"7","key":"10.1016\/j.vaccine.2012.07.065_bib0250","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2012.07.065_bib0255","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.065_bib0260","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2012.07.065_bib0265","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12010900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12010900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T09:11:24Z","timestamp":1594545084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12010900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":53,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0264410X12010900"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.07.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}